Nintedanib in the treatment of interstitial lung disease associated with systemic sclerosis: A justified hope?

被引：0
|
作者：
Hachulla, E. [1 ]
机构：
[1] Hop Claude Huriez, Ctr Reference Malad Autoimmunes & Autoinflammatoi, Serv Med Interne & Immunol Clin, F-59037 Lille, France
来源：
REVUE DE MEDECINE INTERNE | 2019年 / 40卷 / 12期
关键词：
Nintedanib; Systemic sclerosis; Interstitial lung disease; SCLERODERMA LUNG; CONTROLLED-TRIAL; PLACEBO; CYCLOPHOSPHAMIDE;
D O I：
10.1016/j.revmed.2019.08.009
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：775 / 777
页数：3
相关论文
共 50 条
  • [21] Effect of Nintedanib on KL-6 in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
    Assassi, Shervin
    Denton, Christopher
    Cutolo, Maurizio
    Luckhardt, Tracy
    Diefenbach, Claudia
    Ittrich, Carina
    Alves, Margarida
    Kuwana, Masataka
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 828 - 829
  • [22] Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease
    Allanore, Yannick
    Khanna, Dinesh
    Smith, Vanessa
    Aringer, Martin
    Hoffmann-Vold, Anna-Maria
    Kuwana, MasatakaKuwana
    Merkel, Peter A.
    Stock, Christian
    Sambevsk, Steven
    Denton, Christopher P.
    RHEUMATOLOGY, 2024, 63 (03) : 639 - 647
  • [23] Spontaneous pneumothorax during nintedanib therapy in patients with systemic sclerosis-associated interstitial lung disease
    Sumi, Toshiyuki
    Uehara, Hirofumi
    Tada, Makoto
    Keira, Yoshiko
    Kamada, Koki
    Shijubou, Naoki
    Yamada, Yuichi
    Nakata, Hisashi
    Mori, Yuji
    Chiba, Hirofumi
    RESPIROLOGY CASE REPORTS, 2021, 9 (03):
  • [24] Interstitial lung disease in systemic sclerosis - Treatment
    Hellmich, B
    Schnabel, A
    Bauer, T
    Schatz, H
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2002, 127 (10) : 520 - 522
  • [25] Current treatment of systemic sclerosis-associated interstitial lung disease
    Bes, Cemal
    Cetinkaya, Erdogan
    TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, 2022, 70 (01): : 85 - 92
  • [26] Recent advances in the treatment of systemic sclerosis associated interstitial lung disease
    Kamenova, Antoniya
    Tzouvelekis, Argyris
    Margaritopoulos, George A.
    FRONTIERS IN MEDICINE, 2023, 10
  • [27] Efficacy of Cyclophospamide in the Treatment of Interstitial Lung Disease Associated with Systemic Sclerosis
    Espinosa, Gerard
    Pilar Simeon, Carmen
    Plasin, Miguel Angel
    Xaubet, Antoni
    Munoz, Xavier
    Fonollosa, Vicent
    Cervera, Ricard
    Vilardell, Miguel
    ARCHIVOS DE BRONCONEUMOLOGIA, 2011, 47 (05): : 239 - 245
  • [28] CONTINUED TREATMENT WITH NINTEDANIB IN PATIENTS WITH LIMITED CUTANEOUS SYSTEMIC SCLEROSIS (LCSSC) AND INTERSTITIAL LUNG DISEASE (ILD)
    Allanore, Y.
    Khanna, D.
    Smith, V.
    Aringer, M.
    Hoffmann-Vold, A. M.
    Kuwana, M.
    Merkel, P. A.
    James, A.
    Sambevski, S.
    Alves, M.
    Denton, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 251 - 252
  • [29] ELIGIBILITY FOR ANTI-FIBROTIC TREATMENT WITH NINTEDANIB OF PATIENTS WITH SYSTEMIC SCLEROSIS RELATED INTERSTITIAL LUNG DISEASE
    De Lorenzis, E.
    Natalello, G.
    Verardi, L.
    Gigante, L.
    D'agostino, M. A.
    Bosello, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 687 - 687
  • [30] Nintedanib: new indication for systemic sclerosis-associated interstitial lung disease (December, 10.1080/14397595.2019.1696505, 2019)
    Kuwana, Masataka
    Azuma, Arata
    MODERN RHEUMATOLOGY, 2020, 30 (02) : 225 - 231
12345